The therapeutic application of Энцетрон-СОЛОфарм centers on providing support for neurological functions in conditions where the brain’s structural integrity or blood supply has been compromised. Its use is relevant across domains that focus on providing additional symptomatic support and managing symptoms that interfere with daily functioning.

Key Therapeutic Applications

This agent is commonly used for supportive management during the acute and subacute phases of conditions like ischemic or hemorrhagic stroke and traumatic brain injury (TBI). It also assists in the long-term management of cognitive impairment associated with cerebral vascular insufficiency. The agent is applied in addressing symptom clusters related to: functional neurological deficits (motor, speech), difficulties with memory and attention, and residual manifestations such as persistent headaches, dizziness, and emotional lability.

The primary benefit is to assist with maintaining functional stability during rehabilitation and may assist with maintaining functional stability when symptoms are more noticeable. The overall approach is supportive: “The agent is applied when conditions produce significant symptomatic burden and supportive symptom management is appropriate.”

QuickFact

Clinical Context: Supportive Management for Cognitive and Functional Strain

Энцетрон-СОЛОфарм provides supportive relief for symptoms that create noticeable functional strain, helping to ease the overall symptom load, and may help patients cope more steadily during symptomatic periods associated with acute or chronic symptomatic changes.

Regulatory References

1. NIH MedlinePlus overview of Citicoline

The eligibility profile for Энцетрон-СОЛОфарм (Citicoline) is strictly defined by regulatory labeling, establishing clear rules for who may and may not use the medicine.

Absolute Contraindications

Use of this medicine is prohibited in two main groups:

• Patients with documented hypersensitivity or allergy to the active substance, Citicoline, or any of the product’s excipients.
• Individuals with hypertonia of the parasympathetic nervous system (increased parasympathetic tone).

Age and Physiological Restrictions

Conditional Use and Caution

Regulatory documents advise caution when administering the medicine to patients presenting with certain clinical conditions. This includes those with persistent intracranial hemorrhage, Parkinson's disease, a history of depression, or the metabolic disorder Trimethylaminuria.

Interactions with other medicines and products

The following information describes the official interaction patterns for Энцетрон-СОЛОфарм (Citicoline) as documented in governmental regulatory prescribing information, focusing strictly on reported constraints.

The official regulatory profile strictly defines these interaction constraints for patient safety and compliance. The most significant constraint involves the formal contraindicated combination with Meclofenoxate, where the co-administration of this agent is explicitly disallowed. A separate pharmacodynamic interaction is officially noted with L-dopa, where co-administration results in an enhancement of L-dopa's therapeutic effects. In addition to drug-drug interactions, the official labeling mandates a clear substance restriction on alcohol, which must be avoided throughout the course of treatment. No known pharmacokinetic interactions, such as those related to specific CYP enzymes or drug transporters, or population-specific interaction considerations are explicitly detailed in regulatory summaries.

Энцетрон-СОЛОфарм operates by binding with high affinity to a specific receptor site located on the surface of osteoclasts. This selective binding event initiates a distinct intracellular signaling cascade. This cascade results in the direct inhibition of key enzymes necessary for the physiological function and survival of the osteoclast cell. This cellular process leads to a direct reduction in the activity and overall population of mature osteoclasts. The consequence of this cellular effect is a dose-dependent reduction in the rate of bone resorption and subsequent decrease in the loss of bone mineral density. The primary mechanism of action involves the modulation of the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption processes. This specific mechanistic cascade, achieved via targeted receptor binding, influences the structural integrity and inherent strength of bone tissue through the alteration of downstream molecular signaling pathways.

Official Administration Guidelines for Citicoline

Энцетрон-СОЛОфарм (Citicoline) must be administered strictly according to the procedures outlined in prescribing information, which specify both the route and precise dosing parameters.

This structure ensures adherence to the standardized protocol defined for administering the medicine. The official instructions mandate a specific route and dose, while also detailing the mandatory procedural constraints for safe administration, particularly concerning injection speed and patient-specific factors.

Research Evidence / Overview of Studies for Энцетрон-СОЛОфарм

Evidence for Use in Acute Ischemic Stroke (Acute & Subacute Phases)

Clinical trials have been conducted for the use of Энцетрон-СОЛОфарм in adults who have experienced a moderate to severe ischemic stroke. Research has explored the use of this agent in studies that include Randomized Controlled Trials (RCTs) and larger aggregated analyses, known as meta-analyses. These trials were primarily used in research exploring how symptoms change over time immediately following the stroke event. Outcomes measured focused on assessing outcomes reflecting daily functioning or activity level, such as a person's ability to perform daily tasks, and tracking the severity of any remaining neurological issues over a short time interval.

Studies have monitored outcomes related to systemic or functional imbalance in the observed populations in the months after a stroke, typically tracking for up to 90 days. Findings across the available evidence have been mixed. While some meta-analyses described aggregated patterns in functional scales, certain major, large-scale RCTs conducted during research exploring short-term symptom changes reported findings that did not consistently align with those aggregated descriptions across all measured outcomes. The evidence base for this application is generally categorized as Moderate.

Evidence for Use in Chronic Cognitive Impairment

The medication was studied in research contexts involving cognitive impairment that is associated with cerebral vascular insufficiency. Study designs include RCTs and observational studies, typically focusing on older adults, including those with milder forms of cognitive impairment linked to vascular issues. Outcomes examined included various tests to track changes in cognitive function, particularly memory, attention, and general problem-solving ability, over longer defined time intervals.

Research describes patterns observed in the studies, with some findings related to global cognitive scores being monitored compared to control groups. Studies monitored outcomes related to systemic or functional imbalance over follow-up durations that sometimes extended up to two years. The available research for this application is generally categorized as Moderate.

What is Still Uncertain About Энцетрон-СОЛОфарм Research

The research provides a framework for understanding how this agent was studied for several neurological conditions. However, the overall evidence quality varies across studies, leading to certain areas of uncertainty. Key gaps include the inconsistent results reported among some of the largest, best-designed clinical trials for stroke and TBI (Traumatic Brain Injury). Additionally, follow-up durations were limited in many studies, meaning data for long-term outcomes remains insufficient. Research provides context but not individual predictions, and findings reflect group patterns, highlighting what is known — and what is still uncertain — about the agent’s role in the broader evidence landscape.

Key Studies & References

1. Efficacy of Citicoline in the Treatment of Acute Traumatic Brain Injury: A Randomized, Double-Blind, Placebo-Controlled Trial (COBRIT)
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC Code N06BX06

Common questions about Энцетрон-СОЛОфарм (FAQ)

Q: Is Энцетрон-СОЛОфарм intended for short-term use in the acute phase of a stroke?

The official indications state that this medicine is used during both the acute phase and the subsequent recovery phase following a cerebral infarction, which is a type of stroke. The regulatory documentation describes this agent as applicable in the context of both the immediate and rehabilitative phases.

Q: Is Энцетрон-СОЛОфарм related to natural choline supplements?

The active ingredient, Citicoline, is a synthetic compound that is chemically identical to a natural substance called Cytidine 5'-diphosphocholine (CDP-choline), which is found in the human body. This substance is recognized for its role in maintaining the structural integrity of nerve cell membranes.

Q: What does the official information say about using Энцетрон-СОЛОфарм for traumatic brain injury?

Regulatory documentation specifies that the medication is indicated for cerebral insufficiency—such as issues with memory, concentration, and disorientation—that results from head trauma or brain injury.

Q: Is a temporary headache a common experience when beginning a course of Энцетрон-СОЛОфарм?

Official information classifies headache as a very rare undesirable effect, meaning it is reported in less than 1 in 10,000 users. Based on regulatory data, the occurrence of a temporary headache when starting treatment is considered infrequent.

Q: Is it typical to experience mild restlessness or insomnia when taking Энцетрон-СОЛОфарм?

Insomnia and excitement are listed in official regulatory documents as very rare psychiatric adverse events. Therefore, the likelihood of experiencing restlessness or difficulty sleeping during the use of this medication is described as low.

Q: Can Энцетрон-СОЛОфарм cause changes in blood pressure, according to the official documentation?

Yes, the official documentation notes that very rare cardiovascular effects have been reported. These may include changes in blood pressure, specifically arterial hypotension (low blood pressure) or hypertension (high blood pressure).

Q: How quickly do patients typically begin to experience the described therapeutic effects of Энцетрон-СОЛОфарм?

Pharmacokinetic studies, which track how the drug moves through the body, indicate that the active substance is rapidly absorbed. Plasma concentrations show a biphasic peak, appearing at approximately one hour and again at 24 hours after oral administration.

Q: Can Энцетрон-СОЛОфарм be used by patients with kidney function impairment?

Official regulatory labels do not explicitly detail data on the effects of kidney (renal) insufficiency on the drug's safety profile or pharmacokinetics. Specific guidance for patients with impaired kidney function is therefore not detailed in the available regulatory summaries.

Q: What are the differences in the documented use of Энцетрон-СОЛОфарм between vascular diseases and trauma?

The official indications categorize use based on the underlying issue: Vascular diseases relate to cognitive dysfunction caused by cerebrovascular issues, and trauma relates to cerebral insufficiency resulting from head injury. The product is regulated for use in the context of these two distinct clinical scenarios.

Q: Does Энцетрон-СОЛОфарм have any described effect on mood, depression, or anxiety levels?

The official safety profile notes very rare psychiatric adverse events, such as excitement and hallucinations. Furthermore, regulatory documentation advises that caution is warranted when administering the medication to patients who have a history of depression.

Q: Is Энцетрон-СОЛОфарм available in forms other than ampules for injection?

Yes, while the medicine is often administered by injection (ampules), the active substance is also available in oral forms, such as tablets or solution/syrup. The authorized administration routes listed include oral, intravenous, and intramuscular use.

Q: What is the research status on Энцетрон-СОЛОфарм for general age-related memory issues?

Research has suggested that the active substance, Citicoline, has been examined in studies for its potential role in memory function in older adults experiencing age-related memory impairment. These studies focus on general cognitive support, which is separate from the drug's official indications in acute injury or vascular disease.

Q: Is the term 'recovery period' defined differently for ischemic stroke versus hemorrhagic stroke when using this drug?

While the active substance has been tested in clinical trials for both ischemic (clot-related) and hemorrhagic (bleed-related) stroke, the official regulatory indications primarily focus on cerebral infarction (ischemic stroke). The specific clinical definition of 'recovery period' is detailed based on the official indication.

Q: What is the half-life of Энцетрон-СОЛОфарм as described in pharmacokinetics data?

Pharmacokinetics data reports that the medicine has a biphasic elimination half-life. The first phase is approximately 3.5 hours, and the second phase, reflecting the longer elimination of metabolites, is approximately 125 hours.

Q: Are there age limitations for using Энцетрон-СОЛОфарм in children or adolescents?

Official documentation restricts the use of this medicine in children and adolescents. The regulatory summary notes that use is generally not recommended due to insufficient safety data in this age group.

Q: Why is Энцетрон-СОЛОфарм often given in an injection form initially?

The injection forms (intravenous or intramuscular) are typically utilized in acute care settings, such as during the initial phase of a stroke. Regulatory prescribing information notes that these routes are used for administration in the acute phase of treatment.

Q: How does the formulation of Энцетрон-СОЛОфарм influence its absorption?

The active substance is highly water-soluble, which is noted to contribute to its reported bioavailability of over 90%. When taken orally, it is absorbed into the bloodstream as its primary breakdown products, choline and cytidine.

Q: Is the effect of Энцетрон-СОЛОфарм cumulative over time?

Studies indicate that the components of the active substance are integrated into the body's metabolic pathways. This process is involved in the synthesis of structural phospholipids, which are the building blocks of nerve cell membranes.

Q: Are there specific nootropic compounds that are officially advised not to be combined with Энцетрон-СОЛОфарм?

Yes, regulatory information explicitly warns against combining this medicine with other compounds. Specifically, co-administration with products containing meclofenoxate (clophenoxate) is formally prohibited.

Q: Does Энцетрон-СОЛОфарм have any known effect on heart rate?

Official documents report that very rare cardiovascular adverse effects have occurred, which involve changes in heart rate. These reported changes include both bradycardia (a slow heart rate) and tachycardia (a fast heart rate).

How to Store and Dispose of Энцетрон-СОЛОфарм?

This information reflects the mandatory storage and disposal rules documented in official regulatory labeling.

Official Storage Conditions

Handling and Disposal Requirements

The solution for injection is strictly intended for single use only and must be administered immediately after opening the container; any remaining portion must be discarded.

Regulatory instructions require that unused or expired medicine must not be disposed of via wastewater or household waste. Instead, individuals must consult a pharmacist for the proper method of pharmaceutical disposal to protect the environment.